1 year ago
Zenex Animal Health Considers Sale or IPO, Potentially Valued at $1 Billion
Imagine a company that makes medicine for animals, called Zenex.
The people who own parts of it are thinking about selling it to someone else or letting regular people buy shares in the stock market (IPO).
This could make the company worth over a billion dollars!
Some big investors like Multiples and CPPIB are involved.
The company's sales went up, but their profit went down a little.
The market for animal medicine in India is expected to grow a lot in the next few years, which means more people are buying medicine for their pets and farm animals.
Zenex Animal Health's investors are exploring a potential sale or IPO.
The veterinary drug maker could be valued at over $1 billion.
Investors including Multiples Alternatives and CPPIB are involved.
The company's revenue was ₹823.6 crore in FY24, with a profit of ₹14.9 crore.
The Indian veterinary medicine market is projected to reach $4.17 billion by 2033.
- Who
- Investors of Zenex Animal Health, including Multiples Alternatives, Rare Enterprises, CPPIB, and IFC.
- What
- Zenex Animal Health's investors are considering a sale or IPO.
- Where
- India
- When
- An investment banker is likely to be appointed soon.
- Why
- To generate an exit plan for investors.
Current Zenex Investors
Potential Buyers
Financial Gains
Current Zenex Investors
Benefit from sale or IPO.
Potential Buyers
Benefit from sale or IPO.
Key facts
- Potential Valuation
- Over $1 billion
- Key Segments
- Livestock, Poultry, Exports
- FY24 Revenue
- ₹823.6 crore
- FY24 Profit
- ₹14.9 crore
- Brands
- More than 250
- Vet Relationships
- 100,000+
Sources
Related news
NSE IPO Day 3: Retail Book Fills, GMP Slips
NSE IPO Opens After Decade-Long Wait, With Strong Interest
NSE IPO Could Deliver ₹16,500 Crore Shareholder Gains
NSE IPO Opens September 17 With No Shareholder Quota
NSE IPO Could Deliver Huge Returns to Selling Shareholders
